Last reviewed · How we verify

NCT04440618: COROSAS

Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

Status unknown Last updated 14 January 2021
What this trial tests

trial in Obstructive Sleep Apnea-hypopnea in 30 participants. Status unknown.

Timeline
30 July 2020
Primary endpoint
30 May 2021
30 June 2021

Quick facts

Lead sponsorPoitiers University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date30 July 2020
Primary completion30 May 2021
Estimated completion30 June 2021
Sites1 location across France

Conditions studied

Sponsor

Poitiers University Hospital

Who can join

18 and older, any sex, with Obstructive Sleep Apnea-hypopnea or Oropharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea-hypopnea

Currently open trials in the same condition.

Other Poitiers University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04440618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing